Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome
- 1 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 22 (5), 526-+
- https://doi.org/10.1038/s41556-020-0497-9
Abstract
Interstitial deletion of the long arm of chromosome 5 (del(5q)) is the most common structural genomic variant in myelodysplastic syndromes (MDS)(1). Lenalidomide (LEN) is the treatment of choice for patients with del(5q) MDS, but half of the responding patients become resistant(2) within 2 years. TP53 mutations are detected in similar to 20% of LEN-resistant patients(3). Here we show that patients who become resistant to LEN harbour recurrent variants of TP53 or RUNX1. LEN upregulated RUNX1 protein and function in a CRBN- and TP53-dependent manner in del(5q) cells, and mutation or downregulation of RUNX1 rendered cells resistant to LEN. LEN induced megakaryocytic differentiation of del(5q) cells followed by cell death that was dependent on calpain activation and CSNK1A1 degradation(4,5). We also identified GATA2 as a LEN-responsive gene that is required for LEN-induced megakaryocyte differentiation. Megakaryocytic gene-promoter analyses suggested that LEN-induced degradation of IKZF1 enables a RUNX1-GATA2 complex to drive megakaryocytic differentiation. Overexpression of GATA2 restored LEN sensitivity in the context of RUNX1 or TP53 mutations by enhancing LEN-induced megakaryocytic differentiation. Screening for mutations that block LEN-induced megakaryocytic differentiation should identify patients who are resistant to LEN.Funding Information
- Associazione Italiana per la Ricerca sul Cancro (21267)
- Leukemia and Lymphoma Society of Canada (515899)
- Terry Fox Research Institute (1074)
- Gouvernement du Canada | Canadian Institutes of Health Research (PJT-166051, PJT-162131)
- Genome British Columbia (121AML)
This publication has 36 references indexed in Scilit:
- SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5qClinical Lymphoma Myeloma and Leukemia, 2018
- Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutationsHaematologica, 2016
- A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromesNature Medicine, 2016
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDSNature, 2015
- Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–CBFβ interactionProceedings of the National Academy of Sciences of the United States of America, 2012
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideBlood, 2011
- TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease ProgressionJournal of Clinical Oncology, 2011
- Unraveling the Molecular Pathophysiology of Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- Identification of a Primary Target of Thalidomide TeratogenicityScience, 2010
- Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progressionAnnals of Hematology, 2009